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ABSTRACT 1 
 2 
INTRODUCTION: Whilst total hip (THR) and knee replacements (TKR) successfully reduce pain 3 
associated with chronic joint pathology, this infrequently translates into increased physical activity. 4 
This is a challenge given that over 50% of individuals who undergo these operations are physically 5 
inactive and have medical comorbidities such as hypertension, heart disease, diabetes and depression. 6 
The impact of these diseases can be reduced with physical activity. This trial aims to investigate the 7 
effectiveness of a behaviour change physiotherapy intervention to increase physical activity compared 8 
to usual rehabilitation after THR or TKR. 9 
 10 
METHODS AND ANALYSIS: The PEP-TALK trial is a multi-centre, open-labelled, pragmatic randomised 11 
controlled trial. 260 adults who are scheduled to undergo a primary unilateral THR or TKR and are 12 
moderately inactive or inactive, with comorbidities, will be recruited across eight sites in England. 13 
They will be randomised post-surgery, prior to hospital discharge, to either six, 30-minute weekly 14 
group-based exercise sessions(control), or the same six-weekly, group-based, exercise sessions each 15 
preceded by a 30-minute cognitive behaviour approach discussion group. Participants will be 16 
followed-up to 12 months by postal questionnaire. The primary outcome is the University of California 17 
Los Angeles (UCLA) Physical Activity Score at 12 months. Secondary outcomes include: physical 18 
function, disability, health-related quality of life, kinesiophobia, perceived pain, self-efficacy and 19 
health resource utilisation.  20 
 21 
ETHICS AND DISSEMINATION: Research ethics committee (REC) approval was granted by the NRES 22 
Committee South Central (Oxford B - 18/SC/0423). Dissemination of results will be through peer-23 
reviewed, scientific journals and conference presentations. 24 
 25 
TRIAL ISRCTN REGISTRATION NUMBER: ISRCTN29770908 26 
PROTOCOL VERSION: Version 4.0 – Date: 17th September 2019 27 
STATUS: trial recruitment is ongoing and is expected to be completed by 1st April 2020. 28 
Keywords: arthroplasty; osteoarthritis; rehabilitation; physical activity; exercise; cognitive 29 
behavioural  30 
 31 
STRENGTHS AND LIMITATIONS OF THIS STUDY 32 
• The effectiveness of a behaviour change physiotherapy intervention to increase physical 33 
activity compared to usual rehabilitation after THR or TKR will be demonstrated with a 34 
pragmatic clinical trial design. 35 
• Functional, behavioural and psychological outcomes will provide evidence to determine the 36 
mechanisms by-which the intervention is or is not effective. 37 
• A multi-centre recruitment approach will provide greater external validity across population 38 
characteristics in England.  39 
• It is not possible to blind participants to the rehabilitation treatments given the participatory 40 
nature of the interventions. 41 
• The group-based intervention may be challenging to ensure sufficient numbers within each 42 
group as participants enter the trial. 43 
3 
 
INTRODUCTION 1 
 2 
Total Hip (THR) and Total Knee Replacement (TKR) are two highly successful orthopaedic procedures 3 
which reduce pain for people with osteoarthritis.[1,2] Over 206,000 THR and TKRs were performed in 4 
the United Kingdom (UK) in 2018.[1] Approximately 90% of patients are satisfied following THR and 5 
TKR,[2] with significant improvements in pain and physical function after three to 12 months.[2,3]  6 
Historically, it has been assumed that people become more active following THR or TKR through the 7 
amelioration of joint pain.[4] However, the current literature suggests physical activity, at best, 8 
remains the same from pre- to post-operatively, and in some instances declines.[4,5]  9 
People following THR and TKR have reported a number of challenges which make engaging in physical 10 
activity difficult, most notably psychosocial barriers and fear avoidance beliefs.[6] Such barriers 11 
include receiving insufficient and inconsistent information on being more physically active, fear of 12 
damaging joint replacements and causing pain, and not being able to goal-set or problem-solve 13 
physical activities within individual’s lifestyles.[6] Whilst previous international guidance as 14 
knowledged the importance of physical activity on health and wellbeing, people following THR and 15 
TKR have acknowledged these difficulties in being more active.[6] They have cited limited support or 16 
guidance currently offered on how to overcome these problems post-operatively.[6] 17 
Not being physically active after joint replacement can have a major negative impact on a person’s 18 
health and a burden on the National Health Service (NHS). Medical co-morbidities are common in this 19 
population. These include hypertension (56%),[7] cardiovascular disease (20%),[8] diabetes (16%)[8] 20 
and multi-joint pain (57%).[7] Twenty-seven percent of people who undergo joint replacement have 21 
three to four comorbidities.[8] Medical comorbidities have a significant negative impact on both 22 
health-related quality of life (HRQoL) and result in a societal burden.[9,10] Participating in regular 23 
physical activity can decrease the risk of cardiovascular disease by 52%,[11] diabetes by 65%,[12] and 24 
some cancers by 40%.[13] It is associated with a reduction in all-cause mortality by 33% and 25 
cardiovascular mortality by 35%.[14]  26 
Current rehabilitation following THR and TKR in the UK, as advocated by the British Orthopaedic 27 
Association, centres around regaining joint movement, strength and gait (walking pattern) re-28 
education.[15] There is currently no evidence informing patients or healthcare professionals on how 29 
to increase physical activity following THR and TKR. Previous research has demonstrated that 30 
behaviour-change interventions can effectively increase physical activity across the lifespan.[16-18] 31 
However, following joint replacement, people have specific psychological needs and challenges which 32 
differ to the non-joint replacement population.[6] Therefore, a specific intervention tailored to this 33 
population's health beliefs, including fear avoidance regarding implant survival, dislocation and 34 
increased knowledge on the impact of physical inactivity on other comorbidities, is required. 35 
Accordingly, the purpose of this trial is to answer the research question “following a primary THR or 36 
TKR, does a group exercise and behaviour-change intervention targeted to increase physical activity 37 
participation increase HRQoL and clinical outcomes over the initial 12 post-operative month compared 38 
to group exercise alone?” 39 
 40 
METHODS AND ANALYSIS 41 
 42 
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Trial Design 1 
This is a two-arm, pragmatic, parallel, multi-centre, randomised controlled superiority trial (RCT) to 2 
assess the effectiveness of a group exercise and behaviour-change intervention aimed to increase 3 
physical activity in people following THR or TKR. Nine UK NHS hospitals are involved in the trial across 4 
England. The study flow chart is presented as Figure 1. Table 1 presents a summary of trial objectives, 5 
outcome measures and time points.  6 
 7 
Trial Participants 8 
A minimum of 260 participants will be recruited. 9 
Participants are eligible if they are:  10 
• Due to undergo primary (first-time) unilateral THR or TKR where the indication for surgery is 11 
degenerative joint pathology (not trauma).  12 
• Aged 18 years and over. 13 
• Classified as ‘moderately inactive’ or ‘inactive’ using on the General Practice Physical Activity 14 
Questionnaire (GPPAQ).[19] 15 
• Have a Charlson Comorbidity Index (CCI) of ≥ 1 point.[20,21]  16 
 17 
Participants are ineligible if they have:  18 
• An absolute contraindication to exercise such as severe cardiovascular or pulmonary disease. 19 
• Cognitive impairment defined as an Abbreviated Mental Test Score (AMTS)[22] of <8. 20 
• A usual place of residence that is a care home. 21 
• Already enrolled onto another trial investigating physical activity, exercise adherence or 22 
behavioural therapy interventions. 23 
• An inability to read and/or comprehend English. 24 
• No access to a working telephone. 25 
 26 
Recruitment 27 
Potential participants will be identified from UK NHS hospital trusts by the clinical team once they 28 
have been listed for THR or TKR. They will be asked whether they would like to know more about the 29 
PEP-TALK trial. There are two options for this: either they will be given a copy of the Participant 30 
Information Sheet (PIS) and asked to contact a member of the Clinical Research Network (CRN) 31 
research team who will provide more information or will be asked whether they are happy for a 32 
member of the CRN research team to contact them directly with more information about the trial. 33 
Verbal consent for the approach will be documented by a clinical team member in the medical notes.  34 
Potential participants will be asked to read the PIS and asked to discuss their potential participation 35 
with anyone who they feel would provide useful advice such as friends, family member or carers. The 36 
number of people provided with the PIS will be recorded to monitor how many participants are 37 
assessed for initial eligibility and sent the PIS. 38 
Eligible patients who agree to participate will provide their consent during the pre-operative 39 
assessment appointment. Participant’s eligibility will then be verified by reviewing the medical notes 40 
and by interviewing the participant using the screening log, Charlson Comorbidity Index (CCI) and 41 
General Practice Physical Activity Questionnaire (GPPAQ) tools. 42 
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Written informed consent (Supplementary File 1) will be obtained prior to any trial-specific 1 
procedures being performed. The baseline case report form (CRF) will be completed at the pre-2 
operative assessments once consent has been taken. After the TKR or THR, eligibility will be confirmed 3 
by the site research team member reviewing the post-operative notes.  4 
 5 
Randomisation, Blinding and Allocation Concealment 6 
Consented participants will be randomised (1:1) to the group exercise and behaviour-change 7 
intervention (intervention group) or group exercise alone intervention (control group) using the 8 
centralised computer randomisation service RRAMP (https://rramp.octru.ox.ac.uk) provided by the 9 
Oxford Clinical Trials Research Unit (OCTRU). This will either be undertaken directly by the site’s 10 
research facilitator or by contacting the trial office over the telephone, who will access the system on 11 
their behalf. Randomisation will be undertaken using a minimisation algorithm to ensure balanced 12 
allocation of participants across the two treatment groups, stratified by: 13 
• Hospital site  14 
• Type of joint replacement (THR or TKR)  15 
• CCI of 1-3 versus ≥4[20,21] 16 
 17 
The minimisation algorithm will be seeded using simple randomisation and will have a probabilistic 18 
element introduced to ensure unpredictability of treatment assignment. 19 
Baseline data will be collected during the pre-operative assessment appointment and prior to 20 
randomisation. Therefore, the central randomisation system will issue a screening identifier (ID). Once 21 
the participant has been randomised, the central randomisation system will provide a participant ID 22 
to be used on all subsequent data collection forms. Sites will be responsible for linking the screening 23 
ID to the participant ID, with all linking information remaining at sites. This will be double-checked 24 
across the CRFs to ensure that the correct paperwork has been provided to the correct participant.  25 
Due to the nature of the intervention, participants and those delivering the rehabilitation will be aware 26 
of the treatment allocation. By virtue of this design, it is not possible to blind participants, 27 
physiotherapists or the site researchers.  28 
Change to the randomisation allocation: An amendment was made to the randomisation ratio in the 29 
minimisation algorithm from 1:1 to 2:1 (Experimental Intervention: Usual Care)  after 75 participants 30 
had been randomised. The expected allocation ratio at the end of trial is likely to approximately 1.5:1. 31 
This was done to ensure a greater number of people are allocated to the experimental intervention, 32 
which is a group-based intervention. As the experimental intervention was designed to have three or 33 
more people per group, early sites have found it difficult to consistently reach this level of participant 34 
numbers with the original 1:1 randomisation allocation. This change was made to reduce the risk of 35 
small numbers in the experimental group. The Trial Management Group (TMG) agreed this on 15th 36 
August 2019. The sample size was increased to 260 to account for this change. This was approved by 37 
the sponsor, Data and Safety Monitoring Committee (DSMC) and research ethics committee. 38 
 39 
Intervention 40 
Usual Care 41 
This will be received by both control and intervention groups. 42 
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In the in-patient setting, all participants will be seen by a physiotherapist a minimum of daily on 1 
weekdays, and will follow their hospital’s standard post-operative pathway. Average hospital length 2 
of stay for people after THR and TKR is five days.[1] Rehabilitation consists of gait re-education, 3 
exercises and advice regarding transferring from bed to chair, toileting and dressing. Advice on 4 
continuation of gait progression and activities of daily living are encouraged by the physiotherapy 5 
team. Once considered medically fit and safe by the multidisciplinary team, patients are discharged. 6 
These follow current, routine, nationwide practice.[23] 7 
All participants attend six-weekly, 30-minute group-based exercise classes within each hospital trust’s 8 
physiotherapy department after THR or TKR. These groups consist of up to 12 people and commence 9 
within four weeks post-randomisation. The principles regarding prescription of group exercises to 10 
increase range of motion, strength and gait pattern are consistent. Whilst the rehabilitation of THR 11 
and TKR focuses on overall lower limb function, all participants following a THR focus on hip exercises, 12 
whereas those following a TKR focus on knee exercises. For this trial, exercise diaries will be provided 13 
and maintained by participants to monitor exercise performance and compliance within and outside 14 
the exercise groups for the six-week intervention period.  15 
Experimental intervention 16 
Participants randomised to the experimental group will receive the same in-hospital care and 17 
physiotherapy prior to hospital discharge. They will also receive the same six-weekly, group-based 30-18 
minute exercise session. The only difference between the two groups is the addition of a 30-minute 19 
group-based (up to 12 people) behaviour change approach intervention prior to the routine 30 20 
minutes of exercise and three telephone-follow-up calls two, four and six weeks after the last group-21 
based session (the PEP-TALK intervention). 22 
The PEP-TALK intervention is theoretically-based within the cognitive-behavioural model of 23 
understanding. It uses evidence-based behaviour change techniques to target internal (cognitions and 24 
behaviours regarding physical activity) and external factors (social and environmental barriers). It 25 
specifically aims to target self-efficacy beliefs and fear-avoidant behaviours. A senior health 26 
psychologist (BF), physiotherapist/cognitive-behavioural therapist (ZH) and senior clinical academic 27 
physiotherapist (TS) developed an in-person, one-day training session. The training was delivered by 28 
BF and TS to all physiotherapists in the trial who were delegated to deliver the PEP-TALK intervention. 29 
The training included role-play, knowledge and understanding testing and supplementary materials 30 
to support on-going learning. All physiotherapists were invited to contact the training team (BF, ZH,TS) 31 
to clarify any training queries throughout the trial.  32 
 33 
In the PEP-TALK sessions, through group discussion, participants and physiotherapists will be 34 
encouraged to develop a positive therapeutic alliance, where the physiotherapist will generate an 35 
environment of trust and belief around individual challenges participant’s have, to support them to 36 
overcome these for sustained physical activity adoption. A treatment log will be completed by the 37 
physiotherapists to record the components of what is discussed across the group in each session.  38 
The PEP-TALK intervention also includes a home-practice element. Participants will be supported with 39 
skills developed in the group, to work at home on challenges, barriers and facilitators to physical 40 
activity behaviour. The ‘home-work’ workbook aims to translate and develop the skills learnt within 41 
the group session into daily life activities. The workbook is designed to be used during the six sessions 42 
although participants are encouraged to keep this as a record and prompt for long-term behaviour 43 
change. The workbook will be referred to in the telephone follow-up calls. The workbook encourages 44 
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reflective activities such as recording physical, emotional and cognitive barriers and facilitators to 1 
physical activity. It also offers problem-solving techniques such as “can you break down a large 2 
physical activity (e.g. ‘getting the house all cleaned for the family coming over’) into tasks which you 3 
can ‘prioritise’, ‘plan’, ‘tolerance level’ and ‘evaluate.’” The workbook also includes other activities to 4 
encourage pacing and behaviour modification, goal-setting to the individual’s health and social needs 5 
and techniques to challenge fear-avoidant behaviours. Education on exercise and the detrimental 6 
effects of physical inactivity will also be discussed. Participants will complete this with their home 7 
exercise plan which solely focuses on lower limb exercises rather than their behaviours and thoughts 8 
around physical activity. 9 
The same trained physiotherapists who deliver the PEP-TALK intervention will, once the participant 10 
has completed their group sessions, deliver three, 20-minute telephone follow-up calls. These will 11 
occur two,  four and six weeks after completing the group sessions. During these follow-up telephone 12 
calls, participant’s goals will be reviewed, any barriers to the completion of these goals will be 13 
identified, and the physiotherapist will review any ‘unhelpful’ and ‘helpful’ thoughts or feelings 14 
towards physical activity which may have arisen since the last consultation. Each telephone call will 15 
close with the development of longer-term physical activity goal-setting and promotion of 16 
empowerment towards physical activity participation using the behavioural principles instilled during 17 
the group intervention. A log will be collected by the physiotherapist to record the components of 18 
what is discussed during the telephone calls.  19 
Delivery  20 
Both the PEP-TALK intervention and exercise groups will be delivered as ‘rolling’ programmes. This 21 
means that new participants can join the group as it runs rather than waiting for a new ‘block’ of 22 
sessions to start. This will allow greater flexibility in allocating participants to join group sessions, 23 
whilst also avoiding a delay between post-operative referral and starting the sessions. The flexible 24 
nature of the experimental intervention also makes this feasible, with no ordering of the content of 25 
intervention sessions which would preclude such a rolling programme.  26 
Contamination 27 
The physiotherapists who deliver the behaviour change sessions will be taught the skills required to 28 
deliver the experimental intervention. These physiotherapists will not be permitted to deliver the 29 
control exercise group intervention during the trial period (and vice versa). This approach mitigates 30 
the risk of contamination. Due to the interventions being delivered in an out-patient setting, there is 31 
a reduced risk of participants sharing their knowledge and experience of the interventions between 32 
the control and intervention groups, further minimising the risk of between-group contamination. 33 
Participants in the control group will not be permitted to join the experimental intervention group’s 34 
exercise sessions (and vice versa). This will also reduce the risk of between-group contamination.  35 
Co-Interventions 36 
During the course of follow-up, participants may require further interventions as part of their recovery 37 
following surgery as per routine NHS practice. Further clinical interventions will be permitted for trial 38 
participants without the participant having to withdraw. If a participant receives additional treatment 39 
to the trial intervention, the details of the treatment received and the reasons will be collected. 40 
Quality Assessment 41 
The trial will be monitored and audited in accordance with the current approved protocol, good clinical 42 
practice,[24] relevant regulations and standard operating procedures (SOPs). 43 
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All designated physiotherapists who deliver the usual care group exercises will be taught about the 1 
standardised control intervention procedures, i.e. clarification on use of exercise diaries and 2 
treatment logs which are additional to usual care.  3 
Designated physiotherapists delivering the behaviour change intervention will attend a one-day, face-4 
to-face course where they will be taught the intervention and processes involved by a member of the 5 
PEP-TALK team who developed the intervention (BF, ZH, TS). In addition, to assess the fidelity to the 6 
trial intervention, a health psychologist (BF) will undertake a debriefing telephone call with each 7 
physiotherapist after they have delivered their first group session. This will allow the trainer to re-8 
enforce any learning required, address any uncertainties and to identify and correct any variation in 9 
the treatment protocol. Finally, each physiotherapist who delivers either the PEP-TALK or control 10 
group intervention will be monitored during a site visit at their 3rd or 4th intervention session. The PEP-11 
TALK intervention physiotherapist will be monitored by a health psychologist (BF) or physiotherapist 12 
with expertise in health psychology (ZH). Control group interventions will be monitored by a practicing 13 
physiotherapist (TS). Sessions will be monitored against the protocol to determine whether there are 14 
issues around fidelity, contamination across groups or adherence/compliance of participants. Where 15 
further training is required, this will be instigated following these visits. Further monitoring visits will 16 
be co-ordinated as required.   17 
 18 
Assessments 19 
Baseline Assessment 20 
Baseline data will be collected prior to randomisation during the pre-operative assessment 21 
appointment, once consent has been obtained. This will include: gender, age, measured height and 22 
weight, CCI, self-reported presence and location of multi-site joint pain, co-morbidities determined 23 
from the medical notes, AMTS, employment status and occupation (when appropriate). Participants 24 
will also complete measures on: physical activity (University of California Los Angeles (UCLA) Activity 25 
Scale;[25] physical function (Lower Extremity Functional Scale (LEFS);[26] disease-specific function 26 
(Oxford Hip Score [27] or Oxford Knee Score [28]); pain (numerical rating scale for pain); self-efficacy 27 
(Generalized Self-Efficacy Scale [29]); fear of movement or kinesiophobia (Tampa Scale for 28 
Kinesiophobia [30]); psychological distress (Hospital Anxiety and Depression Scale (HADS) [31]); 29 
HRQoL (EQ-5D-5L [32]) and the health utilisation questionnaire. 30 
Follow-up data will be collected six- and 12-months post-randomisation. Questionnaires will be sent 31 
to participants by post from the trial office and returned using a pre-addressed, pre-paid envelope. If 32 
participants have not responded within 14 days of posting, the trial team will attempt to telephone 33 
the participant on up to two occasions to remind them to complete the questionnaires. If required, a 34 
second postage of the questionnaires will be provided if requested by the participant during these 35 
follow-up telephone calls. If participants wish not to complete the questionnaires, they will be 36 
provided with the opportunity to complete the UCLA Activity Scale and EQ-5D-5L questionnaires over 37 
the telephone. If these methods fail, the participant would be categorised as a non-responder for that 38 
time-point only. 39 
In an effort to find evidence-based techniques to improve retention and recruitment to RCTs, a study 40 
within a trial (SWAT) will be undertaken. This will examine whether there is a difference in 41 
questionnaire response rate by printing the UCLA Activity Scale on pink rather than white coloured 42 
paper at the six-month time-point. Results of this SWAT will be reported separately to the ‘host’ trial.  43 
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 1 
Outcome Measures 2 
The data collection schedule is presented in Table 2. 3 
 4 
Primary Outcome 5 
• UCLA Activity Scale.[25] This is a reliable and valid self-reported tool to assess physical 6 
activity.[33,34] It assesses global activity levels with a grading system of one out of 10 points 7 
where one equates to “wholly inactive, dependent on others, and cannot leave residence” 8 
and 10 refers to “regularly participants in impact sports”.[25] 9 
 10 
Secondary Outcomes 11 
• LEFS.[26] This is a valid and reliable measure of functional impairment in patients with lower 12 
extremity muscloskeletal condictions (Mehta et al, 2016).  13 
 14 
• Oxford Hip Score (OHS) [27] or Oxford Knee Score (OKS).[28] Both measures have 15 
demonstrated good validity and reliability for people undergoing THR or TKR.[35]   16 
 17 
• Numerical Rating Scale (NRS) for Pain. The NRS has been previously reported as reliable and 18 
valid to assess pain.[36] 19 
 20 
• Generalized Self-Efficacy Scale.[29] This is a reliable and valid measure of self-efficacy.[37,38]. 21 
 22 
• The Tampa Scale for Kinesiophobia.[30] This is a valid and reliable measure of 23 
kinesiophobia.[39,40] 24 
 25 
• HADS.[31] This has been shown as a reliable and valid measure of anxiety and depression.[41]   26 
 27 
• Complications or adverse events (self-reported) which may include: wound or joint infection, 28 
joint dislocation, delayed hospital discharge (measured by length of stay), falls or 29 
musculoskeletal injuries and exacerbations of multi-site joint pain. Adverse events and serious 30 
adverse events will be reported as per the clinical trial unit’s SOP. 31 
 32 
• Health economic and health resource utilisation. We will collect HRQoL using the EQ-5D-33 
5L.[33] Primary sources (i.e. participant log books) will be used to record the duration of the 34 
assessment visits, number and duration of scheduled group sessions, equipment, 35 
consumables, educational material, behaviour change intervention training time; number and 36 
duration of scheduled telephone calls. Frequency of health care resource use will be collected 37 
through patient self-reported questionnaires at follow-ups. The categories of NHS resource 38 
use that will be collected include treatment costs, outpatient visits, any related-inpatient 39 
admissions, rehabilitation visits and any treatment for recurrences and adverse events. Non-40 
medical costs such as caregiving and productivity loss for those in employment at each follow-41 
up will be collected. 42 
 43 
Data Analysis 44 
 45 
10 
 
Sample Size 1 
Originally, 250 participants (125 per arm) are required to detect a standardised effect size of 0.4 with 2 
80% power and 5% (two-sided) significance, and allowing for 20% loss to follow-up. These calculations 3 
are based on the primary outcome, UCLA Activity Scale, at 12 months, assuming a baseline standard 4 
deviation of 2.5 and a between-group difference of one.[33] The minimally clinically important 5 
difference (MCID) has been reported as a within person difference of  0.92 points.[33]  6 
The sample size was increased to 260 to account for the amendment in randomisation proceeedure 7 
from 1:1 to 2:1 group allocation, as described earlier. 8 
 9 
Statistical Analysis 10 
A detailed statistical analysis plan (SAP) will be drafted early in the trial and will be finalised prior to 11 
any primary outcome analysis. This will be reviewed and will receive input from the Trial Steering 12 
Committee (TSC) and the DSMC.  13 
All analyses will be undertaken on the intent-to-treat population, i.e. patients will be analysed as they 14 
were randomised regardless of the treatment received. Sensitivity analyses will be undertaken on the 15 
per-protocol population to assess a range of potential biases that could have resulted from loss-to-16 
follow-up, protocol deviations and withdrawal (including mortality). Numerical and graphical 17 
summaries of all data will be presented including descriptions of missing data at each level.  18 
Estimates of treatment effects will be reported with 95% confidence intervals. The primary outcome 19 
measure, UCLA Activity Scale at 12 months post-randomisation, will be analysed using a mixed-effects 20 
linear regression model adjusted for baseline activity, six month time point and the stratification 21 
factors. Centre will be included as a random-effect to take account of their potential heterogeneity 22 
and type of operation, comorbidity index, and other time points (baseline and six months)  will be 23 
included as fixed-effects. Treatment by six month time point interaction will also be included in the 24 
model to allow time specific treatment effects to be calculated The adjusted difference in the means 25 
with corresponding 95% confidence interval will be reported together with the mean and 95% 26 
confidence intervals for each treatment group. If not normally distributed, then transformation to 27 
normality will be considered. If this is not possible, non-parametric techniques (for example Mann-28 
Whitney or Kruskal-Wallis Test) will be used with no adjustment. Consistency of any observed 29 
intervention effect will be explored using forest plots for various subgroups including site, type of 30 
operation (TKR and THR) and comorbidity index using interactions. No formal testing of interaction 31 
effects will be undertaken as the trial is not powered to detect these and the effect of the intervention 32 
is expected to be similar in the THR and TKR subgroups, although their baseline physical activity may 33 
be different, which will be taken into account in the analysis.  34 
Similar methods will be used to analyse continuous secondary outcomes. Binary and categorical 35 
secondary outcomes, such as complications, will be tabulated to show frequencies and percentages 36 
in each arm. Chi-squared tests or logistic regression will be used to assess statistical significance. 37 
Missing data will be minimised by careful data management. Missing data will be described with 38 
reasons given where available. The number and percentage of individuals in the missing category will 39 
be presented by treatment arm.  40 
The nature and mechanism for missing variables and outcomes will be investigated, and if appropriate, 41 
multiple imputation will be used. Sensitivity analyses will be undertaken assessing the underlying 42 
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missing data assumptions. Any imputation techniques will be fully described in the SAP. Subgroup 1 
analyses, complier average causal effect (CACE) analysis and mediation analyses will be undertaken 2 
after being fully specified in the SAP. Compliance with the intervention is defined as attending at least 3 
four of six group sessions with a minimum of three participants in the group for these sessions and 4 
receiving at least two of the three follow-up phone calls. A priori mediation analysis moderators will 5 
include self-efficacy, fear avoidance, psychological distress to compare the mediation pathways 6 
presented in the BeST intervention [42] to the PEP-TALK intervention.  7 
All data collected on data collection forms will be used, since only essential data items will be 8 
collected. No data will be considered spurious in the analysis since all data will be checked and cleaned 9 
before analysis. 10 
 11 
Health Economics 12 
Respecting an efficient trial design, only if the data indicates clinical effectiveness of the experimental 13 
intervention (for the UCLA Activity Scale and LEFS), will additional funding be sought to analyse the 14 
health economic and utilisation data, to determine the cost-effectiveness of the intervention. 15 
 16 
Data Management 17 
All data will be processed according to the Data Protection Act 2018.[43] All documents will be stored 18 
safely in confidential conditions. Trial-specific documents, except for the signed consent form and 19 
follow-up contact details, will refer to the participant with a unique study participant number, not by 20 
name. Participant identifiable data will be stored separately from trial data. All trial data will be stored 21 
securely in offices or online in secure trial databases, only accessible by the central trial team in Oxford 22 
and authorised personnel. 23 
 24 
Trial Status 25 
The trial is funded for 36 months and commenced in August 2018. Recruitment is expected to be 26 
complete by April 2020 with the final follow-up visit for the final participant completed by April 2021. 27 
The trial will be completed by August 2021. 28 
 29 
Site Locations 30 
Orthopaedic services providing THR and TKRs in nine hospital trusts (eight recruiting sites) and health 31 
providers: (Norfolk and Norwich University Hospitals NHS Foundation Trust, Lewisham and Greenwich 32 
University Hospitals NHS Foundation Trust, Oxford University Hospital NHS Foundation Trust, City 33 
Hospitals Sunderland NHS Foundation Trust, Norwich Spire, Barts Health NHS Trust, North Middlesex 34 
University Hospital NHS Trust, St George’s University Hospital NHS Foundation Trust (treatment site 35 
only), Epsom and St Helier University Hospitals NHS Foundation Trust (recruitment site only)).  36 
 37 
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Patient and Public Involvement 1 
 2 
Patient involvement began during protocol development and continues throughout the trial. A 3 
patient-member will attend all TSC meetings. The same patient-member is a co-investigator, 4 
providing insights into the trial conduct, particularly on data collection processes, and will help 5 
interpret the findings to inform on the implications of the research during the trial’s dissemination 6 
phase. 7 
 8 
ETHICS AND DISSEMINATION  9 
 10 
Ethical approval was gained from the South Central (Oxford B) Research Ethics Committee (Approval 11 
Date: 23Oct2018; Reference Number: 18/SC/0423). The trial was prospectively registered 12 
(ISRCTN29770908). A DSMC and TSC was appointed to independently review the data on safety, 13 
protocol adherence and recruitment to the trial. Direct access will be granted to authorised 14 
representatives from the sponsor and host institution for monitoring and/or audit of the trial to ensure 15 
compliance with regulations. Annoymised data will be shared outside the research team when 16 
required. Researchers outside the trial team may formally request for a specific data set using a data 17 
request form, which will be part of the Data Management Plan (DMP). All such requests will need to 18 
be approved by the TMG. 19 
Reporting of the trial will be consistent with the CONSORT 2010 Statement (patient reported 20 
outcomes and non-pharmcological interventions)[44] and Template for Intervention Description and 21 
Replication (TIDieR)[45] guidelines. A summary of the results and trial materials will be made available 22 
via the trial website on completion of the trial. We will submit the final report to a peer-reviewed 23 
academic journal.  24 
 25 
DISCUSSION 26 
This paper presents the research protocol for the PEP-TALK trial. Following a THR and TKR, only 50% 27 
of people reach World Health Organization recommended levels of physical activity.[15,46,47] Those 28 
who are least likely to meet these levels are people with a higher body mass index and with 29 
comorbidities.[48] These patients have the most to gain from being more physically active. If this trial’s 30 
experimental intervention is shown to be effective, this intervention could have a significant and 31 
sustained impact on improving the management of comorbidities such as diabetes, cardiovascular 32 
diseases, depression and hypertension for over 103,000 people annually in England and Wales.[1] It 33 
is proposed that, in such an instance, this should be considered for implementation in healthcare 34 
services. This could help address the global challenge which multi-morbidities and an ageing 35 
population are expected to have on health and social care services. 36 
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Table 1: PEP-TALK trial objectives, outcome measures and measurement time-points 1 
Objectives Outcome Measures  Time-points 
Primary Objective   
To compare physical activity participation at 12 
months post randomisation between people 
who receive a group exercise and behaviour 
change intervention versus group exercise 
alone following THR or TKR. 
University of California, 
Los Angeles (UCLA) 
activity scale  
Baseline; 6 months; 
12 months (primary 
time-point) 
Secondary Objectives   
To compare the functional outcome between 
people who receive a group exercise and 
behaviour-change intervention versus group 
exercise alone following THR or TKR. 
Lower Extremity 
Functional Scale (LEFS)  
Baseline; 6 months; 
12 months  
To compare the disease-specific pain and 
function between people who receive a group 
exercise and behaviour-change intervention 
versus group exercise alone following THR or 
TKR. 
Oxford Hip Score (OHS) 
[35] or Oxford Knee Score 
(OKS) 
Baseline; 6 months; 
12 months  
To compare the perceived level of pain 
between people who receive a group exercise 
and behaviour-change intervention versus 
group exercise alone following THR or TKR. 
Numerical Rating Scale 
(NRS) for Pain 
Baseline; 6 months; 
12 months  
To compare participant’s self-efficacy between 
those who receive a group exercise and 
behaviour-change intervention versus group 
exercise alone following THR or TKR. 
Generalized Self-Efficacy 
Scale (GSES)  
Baseline; 6 months; 
12 months  
To compare participant’s fear avoidance to 
movement between those who receive a group 
exercise and behaviour-change intervention 
versus group exercise alone following THR or 
TKR. 
The Tampa Scale for 
Kinesiophobia  
Baseline; 6 months; 
12 months  
To compare participant’s psychological distress 
(anxiety and depression) between those who 
receive a group exercise and behaviour-change 
intervention versus group exercise alone 
following THR or TKR. 
Hospital Anxiety and 
Depression Scale (HADS)  
Baseline; 6 months; 
12 months  
To compare participant’s complications and 
adverse events between those who receive a 
group exercise and behaviour-change 
intervention versus group exercise alone 
following THR or TKR. 
Complications or adverse 
events recorded in  the 
CRFs  
6 months; 12 months  
To collect cost-effectiveness data (health 
resource utilisation; direct and indirect costs) of 
a group exercise and a behaviour-change 
intervention versus group exercise alone 
following THR or TKR. 
EQ-5D-5L; Bespoke 
health care resource self-
reported questionnaire 
6 months; 12 months 
  2 
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Table 2: Data collection schedule  1 
Data Time-points and Mode of Data Collection 
Baseline Intervention 
Period 
Month 6  
Post-
Randomisation 
Month 12 Post-
Randomisation 
Face-to-Face Face-to-Face Postal Postal 
Age (years)     
Gender     
Weight (kg)     
Height (cm)     
Admission Date     
Operative procedure (THR or TKR)     
Side of Joint Replacement     
Duration of hip or knee symptoms     
Presence and location of multi-joint pain     
ASA grade     
AMTS     
List of medical co-morbidities     
Physiotherapist exercise class log      
Patient in-session and home exercise diary     
Behaviour change intervention log (group and 
telephone) (physiotherapist completed) 
    
Charlson Comorbidity Score     
Employment status and current occupation 
(when appropriate) 
    
UCLA Activity Score     
Lower Extremity Functional Scale     
Oxford Hip or Knee Score     
Numerical Rating Scale – Pain     
Generalized Self-Efficacy Scale     
Tampa Scale for Kinesiophobia     
Hospital Anxiety and Depression Scale     
EQ-5D-5L      
Health economic/Health utilisation questionnaire     
Complications and adverse events      
Shaded areas represent where these data are being collected. 2 
Assessment intervals following randomisation; each follow-up interval +/- 1 month 3 
AMTS – Abbreviated Mental Test Score; ASA – American Society of Anaesthesiologists classification; cm – 4 
centimetres; kg – kilograms; THR – total hip replacement; TKR – total knee replacement; UCLA – University 5 
College Los Angeles. 6 
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Figure 1: Study flow chart 1 
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  24 
Operation  
Consent Participant and Baseline Data Collection 
to Trial 
 
Verify Eligibility 
Randomisation on Day of Discharge 
Behaviour Change Exercise Group 
(N = 125)  
Out-patient exercise group physiotherapy (6 weekly 
sessions x 1 hour) delivered with a behaviour change 
approach commencing week 4-6 post-operatively 
PLUS 3 telephone follow-on calls 
Standard Exercise Group 
(N = 125) 
Conventional post-operative exercise group 
physiotherapy rehabilitation (6 weekly sessions 
x 30 minutes) commencing week 4-6 post-
operatively 
 6 Month Assessment  
People listed for a THR or TKR in the participating centres 
Screening and Participant Approach Excluded: Not 
Eligible 
12 Month Assessment  
6 Month Assessment  
12 Month Assessment  
In-Patient Rehabilitation  
Excluded: Not 
Eligible 
21 
 
Supplementary File 1: Consent Form 1 
 2 
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 4 
